Kynurenine pathway abnormalities in Parkinson's disease
暂无分享,去创建一个
[1] J. Langston,et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.
[2] R. Beninger,et al. Kynurenic acid-induced protection of neurochemical and behavioural deficits produced by quinolinic acid injections into the nucleus basalis of rats , 1986, Neuroscience Letters.
[3] M. Beal,et al. Cerebral synthesis and release of kynurenic acid: an endogenous antagonist of excitatory amino acid receptors , 1990, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[4] P. Löschmann,et al. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists , 1991, Nature.
[5] R. Tissot,et al. The metabolism of L‐3–0‐methyldopa, aprecursor of dopa in man , 1971, Clinical pharmacology and therapeutics.
[6] R. Ramsay,et al. Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. , 1986, The Journal of biological chemistry.
[7] W. Matson,et al. n-Electrode three-dimensional liquid chromatography with electrochemical detection for determination of neurotransmitters. , 1984, Clinical chemistry.
[8] B. R. Bloem,et al. The MPTP model: versatile contributions to the treatment of idiopathic Parkinson's disease , 1990, Journal of the Neurological Sciences.
[9] R. Schwarcz,et al. Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid , 1984, Neuroscience Letters.
[10] T. Guilarte,et al. Increased Concentrations of 3‐Hydroxykynurenine in Vitamin B6 Deficient Neonatal Rat Brain , 1987, Journal of neurochemistry.
[11] G. Lombardi,et al. The excitotoxin quinolinic acid is present in the brain of several mammals and its cortical content increases during the aging process , 1984, Neuroscience Letters.
[12] N. Sharpless,et al. Dopa and 3-O-methyldopa in cerebrospinal fluid of Parkinsonism patients during treatment with oral L-dopa. , 1971, Clinica chimica acta; international journal of clinical chemistry.
[13] R. Schwarcz,et al. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. , 1983, Science.
[14] T. Stone,et al. Quinolinic acid and other kynurenines in the central nervous system , 1985, Neuroscience.
[15] M. Beal,et al. EC array sensor concepts and data. , 1987, Life sciences.
[16] T. Nagatsu,et al. An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions , 1988, Neuroscience Letters.
[17] M. Cuénod,et al. Identification of quinolinic acid in rat and human brain tissue , 1983, Neuroscience Letters.
[18] M. Hyyppä,et al. Effect of L-dopa on brain monoamines and their metabolites in Parkinson's disease. , 1971, Life sciences. Pt. 1: Physiology and pharmacology.
[19] O. H. Lowry,et al. Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.
[20] B. Rosen,et al. 1‐Methyl‐4‐Phenylpyridinium Produces Excitotoxic Lesions in Rat Striatum as a Result of Impairment of Oxidative Metabolism , 1992, Journal of neurochemistry.
[21] M. Beal,et al. Kynurenine Pathway Measurements in Huntington's Disease Striatum: Evidence for Reduced Formation of Kynurenic Acid , 1990, Journal of neurochemistry.
[22] Joseph B. Martin,et al. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid , 1986, Nature.
[23] A. Pletscher,et al. L-dopa-induced accumulation of 3-O-metyldopa in brain and heart. , 1970, European journal of pharmacology.